PR Newswire Clinical TrialsOriginal article
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Trial StartpaxalisibgemcitabinePositive
AI Analysis
Summary
Kazia Therapeutics announced the first patient has been dosed in the PNOC035 clinical study evaluating paxalisib plus gemcitabine for children and young adults with recurrent or progressive atypical teratoid/rhabdoid tumors (AT/RT), where no approved therapies currently exist.
Clinical Trial Data
NCT ID
Outcome Details
First patient dosed in PNOC035 study
Importance:5/10
Sentiment:
0.60
pediatric oncologybrain cancerAT/RTclinical trial initiationcombination therapy
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 9, 2026 11:30 AM